-
公开(公告)号：US11718641B2
公开(公告)日：2023-08-08
申请号：US17186447
申请日：2021-02-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
CPC classification number: C07J41/0066 , C07J41/0055 , C07J41/0088 , C07J43/003 , C07J43/006 , C07J9/005 , C07J41/0094 , C07J51/00
Abstract: The present invention provides compounds of Formula I,
pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.-
公开(公告)号：US20230234922A1
公开(公告)日：2023-07-27
申请号：US18095155
申请日：2023-01-10
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Kaicheng Zhu , Tao Wang , Jiajun Zhang , Hui Cao , Ruichao Shen , Guoqiang Wang , George G. Wu , Yat Sun Or
IPC: C07D209/42
CPC classification number: C07D209/42
Abstract: The present invention relates to processes for preparing a Compound (1):
or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.-
公开(公告)号：US20230203048A1
公开(公告)日：2023-06-29
申请号：US17983474
申请日：2022-11-09
Applicant: ENANTA PHARMACEUTICALS, INC
Inventor： Guoqiang Wang , Ruichao Shen , Xuechao Xing , Yong He , Matthew C. Rhodes , Yat Sun Or
IPC: C07D487/10 , A61P31/14
CPC classification number: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US20230151019A1
公开(公告)日：2023-05-18
申请号：US17983501
申请日：2022-11-09
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Hui Cao , Wei Li , Xuri Gao , Jiajun Zhang , Xiaowen Peng , Jorden Kass , Ruichao Shen , Guoqiang Wang , Yat Sun Or
IPC: C07D487/10 , A61P31/14
CPC classification number: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US11560368B2
公开(公告)日：2023-01-24
申请号：US17197399
申请日：2021-03-10
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D403/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
Patent Agency Ranking
公开(公告)号：US20220402966A1
公开(公告)日：2022-12-22
申请号：US17324464
申请日：2021-05-19
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US11352363B1
公开(公告)日：2022-06-07
申请号：US17479530
申请日：2021-09-20
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Xuri Gao , Ruichao Shen , Yong He , Jiajun Zhang , Joseph D. Panarese , Hui Cao , Xuechao Xing , Yat Sun Or
IPC: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20220162217A1
公开(公告)日：2022-05-26
申请号：US17479530
申请日：2021-09-20
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Xuri Gao , Ruichao Shen , Yong He , Jiajun Zhang , Joseph D. Panarese , Hui Cao , Xuechao Xing , Yat Sun Or
IPC: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11040998B2
公开(公告)日：2021-06-22
申请号：US16593262
申请日：2019-10-04
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10683279B2
公开(公告)日：2020-06-16
申请号：US15979128
申请日：2018-05-14
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D403/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
-
-
-
-
-
-
-
-
Search Results
98
records
(took 0.029 seconds)
